Keyword: Olumiant (baricitinib)
The 2-mg dose of Eli Lilly and Incyte's arthritis drug picked up an FDA approval after experts flagged safety concerns on the 4-mg dose.
Lilly analysts worry growth could suffer if it doesn't win a nod for both baricitinib doses—and an FDA panel shot down one of them Monday.
Incyte CEO Hervé Hoppenot scored a big pay raise in 2017, even after the FDA rebuffed the highly anticipated RA drug it's developing with Eli Lilly.
Lilly CEO David Ricks has overhauled his team twice since he took over in January, and this time he's focusing on manufacturing, tech and R&D.
Eli Lilly’s RA med baricitinib had been pegged as one of 2017’s hottest launches—and a threat to Pfizer’s Xeljanz. Not anymore.
Eli Lilly beat sales estimates in the second quarter, but the pressure is on for the company to continue to innovate.
Eli Lilly has won a nod from NICE for its anticipated blockbuster and Humira competitor, Olumiant, a drug the FDA rejected in April.
Investors were in the mood for good news from Eli Lilly—and they got a bit of it in its first-quarter earnings report, even as pipeline worries cast a cloud over the numbers.
After a big slowdown in 2016, FDA new drug approvals got off to a hot start in 2017.
Eli Lilly and partner Incyte have received a complete response letter for their highly anticipated rheumatoid arthritis drug baricitinib.